CL2011001918A1 - Use of ezatiostat or a salt of it to prepare a useful medication in the treatment of myelodysplasic syndrome. - Google Patents

Use of ezatiostat or a salt of it to prepare a useful medication in the treatment of myelodysplasic syndrome.

Info

Publication number
CL2011001918A1
CL2011001918A1 CL2011001918A CL2011001918A CL2011001918A1 CL 2011001918 A1 CL2011001918 A1 CL 2011001918A1 CL 2011001918 A CL2011001918 A CL 2011001918A CL 2011001918 A CL2011001918 A CL 2011001918A CL 2011001918 A1 CL2011001918 A1 CL 2011001918A1
Authority
CL
Chile
Prior art keywords
treatment
ezatiostat
salt
prepare
myelodysplasic syndrome
Prior art date
Application number
CL2011001918A
Other languages
Spanish (es)
Inventor
Gail Meng Lixin Brown
Original Assignee
Telik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66221301&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011001918(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Telik Inc filed Critical Telik Inc
Priority to CL2011001918A priority Critical patent/CL2011001918A1/en
Publication of CL2011001918A1 publication Critical patent/CL2011001918A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso de ezatiostat o una sal de el para el tratamiento del síndrome mielodisplásico; composición farmacéutica que comprende a dicho compuesto además de lenalidomida; kit farmacéutico; método de tratamiento para pacientes que han desarrollado intolerancia a la lenalidomida.Use of ezatiostat or a salt thereof for the treatment of myelodysplastic syndrome; pharmaceutical composition comprising said compound in addition to lenalidomide; pharmaceutical kit; treatment method for patients who have developed lenalidomide intolerance.

CL2011001918A 2011-08-09 2011-08-09 Use of ezatiostat or a salt of it to prepare a useful medication in the treatment of myelodysplasic syndrome. CL2011001918A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CL2011001918A CL2011001918A1 (en) 2011-08-09 2011-08-09 Use of ezatiostat or a salt of it to prepare a useful medication in the treatment of myelodysplasic syndrome.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2011001918A CL2011001918A1 (en) 2011-08-09 2011-08-09 Use of ezatiostat or a salt of it to prepare a useful medication in the treatment of myelodysplasic syndrome.

Publications (1)

Publication Number Publication Date
CL2011001918A1 true CL2011001918A1 (en) 2012-08-31

Family

ID=66221301

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011001918A CL2011001918A1 (en) 2011-08-09 2011-08-09 Use of ezatiostat or a salt of it to prepare a useful medication in the treatment of myelodysplasic syndrome.

Country Status (1)

Country Link
CL (1) CL2011001918A1 (en)

Similar Documents

Publication Publication Date Title
CL2015003690A1 (en) Use of pridopidine or a salt thereof to prepare a medication useful in the treatment of huntington's disease.
GT201500053A (en) PHARMACEUTICAL COMPOSITION COVERED WITH REGORAFENIB
GT201400111A (en) SUBSTITUTED TRIAZOLOPIRIDINS
CR20150326A (en) AUTOTAXIN INHIBITORS
CL2013002417A1 (en) Compounds derived from fluoropyridinone; pharmaceutical composition comprising them; and its use in the treatment of bacterial infections.
CL2013000716A1 (en) A prodrug or a salt thereof comprising an exendin-conjugate conjugate; preparation procedure of said prodrug; intermediary compounds; pharmaceutical composition that includes it, useful to improve glycemic control in patients with type 2 diabetes.
CL2013001947A1 (en) Pharmaceutical composition comprising pioglitazone; use of pioglitazone to treat Alzheimer's; composition comprising pioglitazone.
CY1120094T1 (en) PHARMACEUTICAL COMPOSITION INCLUDING DESPR036 EXPANDH-4 (1-39) -LYS6-NH2 FOR USE IN THE TREATMENT OF A NEUROCOLOGICAL PATIENT
DOP2013000244A (en) TRIAZOLOPIRIDINS
MX356728B (en) Pharmaceutical combination for use in the treatment of diabetes type 2.
EA202090683A2 (en) METHODS AND COMPOSITIONS FOR CANCER TREATMENT
CO6920289A2 (en) Topical ophthalmic pharmaceutical composition containing regorafenib.
EA201591830A1 (en) PHARMACEUTICAL COMPOSITIONS, INCLUDING EVEROLIMUS
CL2014001861A1 (en) Compounds derived from benzyl sulfonamide, mogat-2 inhibitors; crystalline compound; pharmaceutical composition; and its use in the treatment of hypertriglyceridemia.
EA201690191A1 (en) PHARMACEUTICAL COMPOSITION FOR THE SLOWLY RELEASE OF LANREOTIDE
PE20150167A1 (en) (R) -NIFURATEL, ITS USE FOR THE TREATMENT OF INFECTIONS AND SYNTHESIS OF (R) AND (S) -NIFURATEL
BR112015016033A2 (en) compositions and methods for treating bacterial infections
ES2722926T3 (en) Combination of levocabastine and fluticasone furoate for the treatment of inflammatory and / or allergic conditions
EA201490041A1 (en) PLASTER CONTAINING DICLOFENAC AND THYOKOLCHICOSID
CL2015001940A1 (en) Formulation comprising a benzothiazolone compound.
PE20161558A1 (en) NEW COMPOUND
BR112015004115A2 (en) pharmaceutical compositions comprising flurbiprofen
CL2016001054A1 (en) Compounds for the treatment of diabetes and complications of diseases derived from it
CL2011001918A1 (en) Use of ezatiostat or a salt of it to prepare a useful medication in the treatment of myelodysplasic syndrome.
CL2014002203A1 (en) Use of modafinil in the treatment of cocaine substitution; Oral pharmaceutical composition containing Modafinil in the form of its dextrogiro enantiomer.